In vitro evaluation of platinum chemotherapy combinations with the ATR inhibitor, ceralasertib (AZD6738)

被引：0
|
作者：
Hall, Sally E. [1 ]
Lau, Alan [2 ]
Dean, Emma [2 ]
Martin, Elizabeth [2 ]
Ottley, Christopher [3 ]
Drew, Yvette [1 ]
Veal, Gareth [1 ]
机构：
[1] Newcastle Univ, Newcastle Upon Tyne, Tyne & Wear, England
[2] AstraZeneca, Cambridge, England
[3] Univ Durham, Durham, England
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-1385
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1385
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Investigating the interaction of the ATR inhibitor, AZD6738, with platinum chemotherapy
    Hall, S.
    Lau, A.
    Dean, E.
    Martin, E.
    Huins, C.
    Ottley, C.
    Veal, G.
    Drew, Y.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E27 - E27
  • [2] ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib
    Wilson, Zena
    Odedra, Rajesh
    Wallez, Yann
    Wijnhoven, Paul W. G.
    Hughes, Adina M.
    Gerrard, Joe
    Jones, Gemma N.
    Bargh-Dawson, Hannah
    Brown, Elaine
    Young, Lucy A.
    O'Connor, Mark J.
    Lau, Alan
    CANCER RESEARCH, 2022, 82 (06) : 1140 - 1152
  • [3] Dose-dependent bioavailability and tissue distribution of the ATR inhibitor AZD6738 (ceralasertib) in mice
    Kiesel, Brian F.
    Guo, Jianxia
    Parise, Robert A.
    Venkataramanan, Raman
    Clump, David A.
    Bakkenist, Christopher J.
    Beumer, Jan H.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (02) : 231 - 242
  • [4] Dose-dependent bioavailability and tissue distribution of the ATR inhibitor AZD6738 (ceralasertib) in mice
    Brian F. Kiesel
    Jianxia Guo
    Robert A. Parise
    Raman Venkataramanan
    David A. Clump
    Christopher J. Bakkenist
    Jan H. Beumer
    Cancer Chemotherapy and Pharmacology, 2022, 89 : 231 - 242
  • [5] Optimising the use of platinum chemotherapies in combination with the ATR inhibitor, AZD6738, in breast cancer
    Huins, Charlie
    Hall, Sally
    Ottley, Christopher
    Veal, Gareth
    Drew, Yvette
    BRITISH JOURNAL OF CANCER, 2018, 119 (11) : 38 - 39
  • [6] Development and Scale-up of a Route to ATR Inhibitor AZD6738
    Goundry, William R. F.
    Dai, Kuangchu
    Gonzalez, Miguel
    Legg, Daniel
    O'Kearney-McMullan, Anne
    Morrison, James
    Stark, Andrew
    Siedlecki, Paul
    Tomlin, Paula
    Yang, Jianbo
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2019, 23 (07) : 1333 - 1342
  • [7] Bridging the gap between in vitro and in vivo: Dose and schedule predictions for the ATR inhibitor AZD6738
    Stephen Checkley
    Linda MacCallum
    James Yates
    Paul Jasper
    Haobin Luo
    John Tolsma
    Claus Bendtsen
    Scientific Reports, 5
  • [8] Bridging the gap between in vitro and in vivo: Dose and schedule predictions for the ATR inhibitor AZD6738
    Checkley, Stephen
    MacCallum, Linda
    Yates, James
    Jasper, Paul
    Luo, Haobin
    Tolsma, John
    Bendtsen, Claus
    SCIENTIFIC REPORTS, 2015, 5
  • [9] Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei
    Dillon, Magnus T.
    Barker, Holly E.
    Pedersen, Malin
    Hafsi, Hind
    Bhide, Shreerang A.
    Newbold, Kate L.
    Nutting, Christopher M.
    McLaughlin, Martin
    Harrington, Kevin J.
    MOLECULAR CANCER THERAPEUTICS, 2017, 16 (01) : 25 - 34
  • [10] Quantification of the preclinical and clinical relationship between pRAD50 and efficacy after treatment with the ATR inhibitor ceralasertib (AZD6738)
    Yates, James William Thomas
    Wilson, Zena
    Jones, Gemma N.
    Harrington, Kevin
    Krebs, Matthew
    Dillon, Magnus
    Pierce, Andrew J.
    Dean, Emma
    Lau, Alan
    CANCER RESEARCH, 2020, 80 (16)
12345